Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Valneva SE VALN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • FR • USD

SharesGrow Score
44/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$18.33
+201%

Valneva SE (VALN) is a Biotechnology company in the Healthcare sector, currently trading at $6.09. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is VALN = $18 (+201% upside).

Valuation: VALN trades at a trailing Price-to-Earnings (P/E) of -3.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.02.

Financials: revenue is $175M, -14.7%/yr average growth. Net income is $115M (loss), growing at -241.1%/yr. Net profit margin is -66% (negative). Gross margin is 38.7% (+28.5 pp trend).

Balance sheet: total debt is $207M against $106M equity (Debt-to-Equity (D/E) ratio 1.95, leveraged). Current ratio is 2.38 (strong liquidity). Debt-to-assets is 52%. Total assets: $399M.

Analyst outlook: 2 / 2 analysts rate VALN as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 33/100 (Fail), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

$18.33
▲ 200.99% Upside
Average Price Target
Based on 2 Wall Street analysts offering 12-month price targets for Valneva SE, the average price target is $18.33, with a high forecast of $26.00, and a low forecast of $14.00.
Highest Price Target
$26.00
Average Price Target
$18.33
Lowest Price Target
$14.00

VALN SharesGrow Score Overview

51/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VALN

✓
VALUE Pass
100/100
VALN trades at a trailing Price-to-Earnings (P/E) of -3.8 (S&P 500 average ~25). Forward PEG 0.02 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.4. Analyst consensus target is $18, implying +195.6% from the current price $6. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
VALN: -14.7%/yr revenue is, -241.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet VALN: Debt-to-Equity (D/E) ratio 1.95 (leveraged), Current ratio is 2.38 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
VALN: Gross margin is 38.7% (+28.5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 2 / 2 analysts rate VALN as buy (100%). Analyst consensus target is $18 (+195.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
VALN: Net profit margin is -66%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range5.429-12.25
Volume91.16K
Avg Volume (30D)64.21K
Market Cap$524.01M
Beta (1Y)1.53
Share Statistics
EPS (TTM)-1.32
Shares Outstanding$84.09M
IPO Date2021-05-05
Employees713
CEOThomas Lingelbach
Financial Highlights & Ratios
Revenue (TTM)$174.66M
Gross Profit$67.52M
EBITDA$-50.47M
Net Income$-115.19M
Operating Income$-81.63M
Total Cash$109.65M
Total Debt$207.25M
Net Debt$97.6M
Total Assets$398.84M
Price / Earnings (P/E)-4.6
Price / Sales (P/S)3
Analyst Forecast
1Y Price Target$15.00
Target High$26.00
Target Low$14.00
Upside+146.3%
Rating ConsensusBuy
Analysts Covering2
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryFR
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS92025Y1038

Price Chart

Track all markets on TradingView
VALN
Valneva SE ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
5.43 52WK RANGE 12.25

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 OPT
OPT
Opthea Limited
$3.41
+1.49%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 TYRA
TYRA
Tyra Biosciences, Inc.
$35.27
-0.98%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.19
+7.40%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message